Assenagon Asset Management S.A. Fate Therapeutics Inc Transaction History
Assenagon Asset Management S.A.
- $60.5 Billion
- Q2 2025
A detailed history of Assenagon Asset Management S.A. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 212,342 shares of FATE stock, worth $263,304. This represents 0.0% of its overall portfolio holdings.
Number of Shares
212,342
Previous 302,899
29.9%
Holding current value
$263,304
Previous $239,000
0.84%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding FATE
# of Institutions
146Shares Held
96.9MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$16 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$12.5 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$9.67 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$5.32 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $120M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...